In today’s recent session, 0.64 million shares of the ProQR Therapeutics N.V (NASDAQ:PRQR) have been traded, and its beta is 0.37. Most recently the company’s share price was $3.67, and it changed around $0.36 or 10.88% from the last close, which brings the market valuation of the company to $299.77M. PRQR at last check was trading at a discount to its 52-week high of $4.62, offering almost -25.89% off that amount. The share price’s 52-week low was $1.13, which indicates that the recent value has risen by an impressive 69.21% since then. We note from ProQR Therapeutics N.V’s average daily trading volume that its 10-day average is 7.1 million shares, with the 3-month average coming to 1.21 million.

ProQR Therapeutics N.V stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended PRQR as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. ProQR Therapeutics N.V is expected to report earnings per share of -0.11 for the current quarter.

ProQR Therapeutics N.V (NASDAQ:PRQR) trade information

Instantly PRQR has been showing a green trend so far today with a performance of 10.88% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.85 on recent trading dayincreased the stock’s daily price by 4.68%. The company’s shares are currently up 85.35% year-to-date, but still down -2.91% over the last five days. On the other hand, ProQR Therapeutics N.V (NASDAQ:PRQR) is 101.65% up in the 30-day period. We can see from the shorts that 0.13 million shares have been sold at a short interest cover period of 0.83 day(s).

The consensus price target as assigned by Wall Street analysts is $3.75, which translates to bulls needing to increase their stock price by 2.13% from its current value. Analyst projections state that PRQR is forecast to be at a low of $2 and a high of $5.

ProQR Therapeutics N.V (PRQR) estimates and forecasts

ProQR Therapeutics N.V share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 89.18 percent over the past six months and at a 18.42% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -37.50% in revenue this quarter, and will report a decrease of -12.50% in the next quarter. The year-over-year growth rate is expected to be 174.10%, up from the previous year.

Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 11.96M in revenue for the current quarter. 4 analysts expect ProQR Therapeutics N.V to make 5.49M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.49M and 6.75M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 703.70%. Forecasts for the next quarter put sales growth at -18.60%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.74%.

PRQR Dividends

ProQR Therapeutics N.V’s next quarterly earnings report is expected to be released on 2024-Aug-08.

ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders

ADAGE CAPITAL PARTNERS GP, L.L.C., with 4.4446% or 3.63 million shares worth $6.02 million as of 2024-06-30, holds the second largest percentage of outstanding shares.